Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study
- 12 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 125 (6), 893-900
- https://doi.org/10.1038/s41416-021-01480-0
Abstract
Background Proton pump inhibitors (PPIs) are associated with microbiome changes of the gut, which in turn may affect the progression of colorectal cancer (CRC). This study aims to assess the associations between PPI use and all-cause and CRC-specific mortality. Methods We selected all patients registered in the Swedish Prescribed Drug Registry who were diagnosed with CRC between 2006 and 2012 (N = 32,411, 54.9% PPI users) and subsequently followed them through register linkage to the Swedish Causes of Death Registry until December 2013. PPI users were patients with ≥1 post-diagnosis PPI dispensation. Time-dependent Cox-regression models were performed with PPI use as time-varying exposure. Results Overall 4746 (14.0%) patients died, with an aHR of 1.38 (95% CI 1.32–1.44) for all-cause mortality comparing PPI users with PPI nonusers. Higher-magnitude associations were observed among male, cancer stage 0−I, rectal cancer and patients receiving CRC surgery. The PPI-all-cause mortality association was also more pronounced comparing new users to non-users (aHR = 1.47, 95%CI 1.40–1.55) than comparing continuous users to non-users (aHR = 1.32, 95%CI 1.24–1.39). The risk estimates for CRC-specific mortality comparing PPI users to PPI nonusers were similar to those for all-cause mortality. Conclusion PPI use after the CRC diagnosis was associated with increased all-cause and CRC-specific mortality.Keywords
Funding Information
- HZ was supported by a UNSW Scientia Fellowship.
- Vetenskapsrådet (2020-01058)
- Svenska Läkaresällskapet
This publication has 50 references indexed in Scilit:
- Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in SwedenBMJ Open, 2013
- Use of Aspirin postdiagnosis improves survival for colon cancer patientsBritish Journal of Cancer, 2012
- Aspirin Use and Survival After Diagnosis of Colorectal CancerJAMA, 2009
- Colorectal cancer risk in relation to use of acid suppressive medicationsPharmacoepidemiology and Drug Safety, 2009
- The completeness of the Swedish Cancer Register – a sample survey for year 1998Acta Oncologica, 2009
- Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studiesThe Lancet, 2007
- Application of lag‐time into exposure definitions to control for protopathic biasPharmacoepidemiology and Drug Safety, 2007
- Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID useGastrointestinal Endoscopy, 2006
- Gastrin promotes human colon cancer cell growth via CCK‐2 receptor‐mediated cyclooxygenase‐2 induction and prostaglandin E2 productionBritish Journal of Pharmacology, 2005
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987